JP2024529976A5 - - Google Patents
Info
- Publication number
- JP2024529976A5 JP2024529976A5 JP2024505311A JP2024505311A JP2024529976A5 JP 2024529976 A5 JP2024529976 A5 JP 2024529976A5 JP 2024505311 A JP2024505311 A JP 2024505311A JP 2024505311 A JP2024505311 A JP 2024505311A JP 2024529976 A5 JP2024529976 A5 JP 2024529976A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- mutation
- pharmaceutical composition
- inhibitor
- immunotherapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163227111P | 2021-07-29 | 2021-07-29 | |
| US63/227,111 | 2021-07-29 | ||
| US202163280430P | 2021-11-17 | 2021-11-17 | |
| US63/280,430 | 2021-11-17 | ||
| PCT/US2022/038903 WO2023009834A2 (en) | 2021-07-29 | 2022-07-29 | Methods of treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024529976A JP2024529976A (ja) | 2024-08-14 |
| JP2024529976A5 true JP2024529976A5 (cg-RX-API-DMAC7.html) | 2025-08-04 |
Family
ID=85088302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024505311A Pending JP2024529976A (ja) | 2021-07-29 | 2022-07-29 | がんを治療する方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20240374605A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4376886A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024529976A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023009834A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12282014B2 (en) | 2015-11-19 | 2025-04-22 | Dana-Farber Cancer Institute, Inc. | Methods of identifying compounds that interfere with ERG-driven misguidance of BAF complexes in TMPRSS2-ERG driven prostate cancers |
| EP3746124A4 (en) | 2018-01-30 | 2021-10-27 | Foghorn Therapeutics Inc. | COMPOUNDS AND THEIR USES |
| US12473334B2 (en) | 2018-10-17 | 2025-11-18 | Dana-Farber Cancer Institute, Inc. | SWI/SNF family chromatin remodeling complexes and uses thereof |
| US12509453B2 (en) | 2019-01-29 | 2025-12-30 | Foghorn Therapeutics Inc. | BRM/BRG1 inhibitors and uses thereof |
| US12384776B2 (en) | 2019-01-29 | 2025-08-12 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| WO2021155264A1 (en) | 2020-01-29 | 2021-08-05 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| WO2021155262A1 (en) | 2020-01-29 | 2021-08-05 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| US12383555B2 (en) | 2020-05-20 | 2025-08-12 | Foghorn Therapeutics Inc. | Methods of treating cancers |
| US12606553B2 (en) | 2021-03-09 | 2026-04-21 | Foghorn Therapeutics Inc. | Crystalline forms, compositions containing same, and methods of their use |
| WO2024086577A1 (en) * | 2022-10-17 | 2024-04-25 | Foghorn Therapeutics Inc. | Methods of reducing or preventing metastases |
| WO2025080767A1 (en) * | 2023-10-10 | 2025-04-17 | Foghorn Therapeutics Inc. | Differentiation and maintenance dosing regimen for fhd 286 (brg1/brm inhibitor) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2900301T3 (es) * | 2013-03-15 | 2022-03-16 | Novartis Ag | Biomarcadores asociados con la inhibición de BRM |
| US10864258B2 (en) * | 2013-04-29 | 2020-12-15 | Trustees Of Dartmouth College | Method for treating pancreatic cancer with Toxoplasma gondii vaccine |
| EP3746124A4 (en) * | 2018-01-30 | 2021-10-27 | Foghorn Therapeutics Inc. | COMPOUNDS AND THEIR USES |
| EP3883580A4 (en) * | 2018-11-21 | 2023-01-04 | Foghorn Therapeutics Inc. | Methods of treating cancers |
| WO2021155262A1 (en) * | 2020-01-29 | 2021-08-05 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
-
2022
- 2022-07-29 US US18/292,582 patent/US20240374605A1/en active Pending
- 2022-07-29 JP JP2024505311A patent/JP2024529976A/ja active Pending
- 2022-07-29 WO PCT/US2022/038903 patent/WO2023009834A2/en not_active Ceased
- 2022-07-29 EP EP22850374.4A patent/EP4376886A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Petroni et al. | Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment | |
| Mohseni et al. | Advances in biology of acute lymphoblastic leukemia (ALL) and therapeutic implications | |
| JP6595024B2 (ja) | B−Raf阻害薬、EGFR阻害薬及び場合によってはPI3K−α阻害薬を含む組合せ医薬 | |
| JP6288726B2 (ja) | 変異flt3増殖性障害の治療剤クレノラニブ(crenolanib) | |
| JP2023512039A5 (cg-RX-API-DMAC7.html) | ||
| JP2022523074A5 (cg-RX-API-DMAC7.html) | ||
| RU2747788C2 (ru) | Комбинированная терапия ингибиторами notch и cdk4/6 для лечения рака | |
| RU2020114632A (ru) | Терапевтические способы, относящиеся к ингибиторам hsp90 | |
| US20250041297A1 (en) | Ret inhibitor for use in treating cancer having a ret alteration | |
| CN109310685B (zh) | 用于治疗癌症的notch和pi3k/mtor抑制剂的组合疗法 | |
| Sharma Lamichhane et al. | Primary malignant mucosal melanoma of the upper lip: a case report and review of the literature | |
| CN113164779A (zh) | 治疗cdk4/6抑制剂耐药性癌症的方法 | |
| TW202332431A (zh) | 用於治療癌症之方法及包含cdk2抑制劑及cdk4抑制劑之給藥方案 | |
| WO2023061472A1 (zh) | 抗her2抗体药物偶联物和酪氨酸激酶抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| JP2023521227A5 (cg-RX-API-DMAC7.html) | ||
| JP2025533719A (ja) | がんの治療のためのkat6阻害剤を含む投与レジメン | |
| ES3037206T3 (en) | Combination therapy | |
| CN117427186A (zh) | 抗her2抗体药物偶联物联合抗pd-l1抗体在制备治疗肺癌的药物中的用途 | |
| WO2020236668A1 (en) | Leukadherin-1 alone or in combination for use in the treatment of cancer | |
| TW200922595A (en) | Organic compounds | |
| CN119497613A (zh) | 使用lsd1抑制剂治疗nf1-突变肿瘤的方法 | |
| TW202200147A (zh) | Belvarafenib用於癌症治療 | |
| Goldman et al. | P47. 03 Telisotuzumab vedotin monotherapy in patients with previously treated c-Met+ advanced non-small cell lung cancer: Stage 2 | |
| WO2026103822A1 (zh) | Ras抑制剂和pd-1或pd-l1抑制剂的组合及其用途 | |
| CN107638424B (zh) | 一种egfr/her2受体酪氨酸激酶抑制剂在制备治疗癌症的药物中的用途 |